Autosomal dominant polycystic kidney disease: updated perspectives
Autor: | Anjay Rastogi, Niloofar Nobakht, Edgar V. Lerma, Maha Al-Baghdadi, Khalid Mohammed Ameen, Kelly Shaffer, Mohammad Kamgar |
---|---|
Rok vydání: | 2019 |
Předmět: |
Oncology
medicine.medical_specialty Tolvaptan Autosomal dominant polycystic kidney disease Kidney Volume Disease 030204 cardiovascular system & hematology urologic and male genital diseases 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Pharmacology (medical) 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Chemical Health and Safety urogenital system business.industry General Medicine medicine.disease female genital diseases and pregnancy complications Pathophysiology Metformin Clinical trial business Safety Research Pravastatin medicine.drug |
Zdroj: | Therapeutics and Clinical Risk Management. 15:1041-1052 |
ISSN: | 1178-203X |
Popis: | Autosomal dominant polycystic kidney disease (ADPKD) is an inherited multisystem disorder, characterized by renal and extra-renal fluid-filled cyst formation and increased kidney volume that eventually leads to end-stage renal disease. ADPKD is considered the fourth leading cause of end-stage renal disease in the United States and globally. Care of patients with ADPKD was, for a long time, limited to supportive lifestyle measures, due to the lack of therapeutic strategies targeting the main pathways involved in the pathophysiology of ADPKD. As the first FDA approved treatment of ADPKD, Vasopressin (V2) receptor blocking agent, tolvaptan, is an urgently awaited advance for ADPKD patients. In our review, we also shed some lights on what is beyond Tolvaptan as there are other medications in the pipeline and many medications have been or are currently being studied in clinical trials such as Tesevatinib, Metformin and Pravastatin, with the goal of slowing the rate of progression of ADPKD by reducing the increase in total kidney volume or maintaining eGFR. Here, we review updates in the perspectives and management of ADPKD. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |